Intensity Therapeutics, Inc.
INTSHealthcare|Biotechnology|US
$3.00
-0.10 (-3.23%)
DCF Value
$8.35
Tangible Book / Share
$2.35
Cash / Share
$2.61
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06263231 A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) | Sarcoma,Soft Tissue | P3 | Recruiting | 333 | RCT, Open-label | INT230-6, Eribulin, Trabectedin, Pazopanib |
| NCT04781725 INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer | Breast Cancer | P2 | Unknown | 90 | RCT, Double-blind | INT230-6 |
| NCT03058289 A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 | Breast Cancer, Head and Neck Cancer | P1P2 | Completed | 111 | Open-label | INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody |